Technological prospection: patents mapping involving compounds for the treatment of L-DOPA-induced dyskinesias

References

• Kaur R, Mehan S, Singh S. Understanding multifactorial architecture of Parkinson’s disease: pathophysiology to management. Neurol Sci. 2019;40:13–23.
   PubMed Web of Science ®Google Scholar
• Bargiotas P, Konitsiotis S. Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments. Neuropsychiatr Dis Treat. 2013;9:1605–1617.
   PubMed Web of Science ®Google Scholar
• Padovan-Neto FE, Ferreira NR, De Oliveira-Tavares D, et al. Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/deltaFosB expression. Neurosci Lett. 2013;541:126–131.
   PubMed Web of Science ®Google Scholar
• Carta M, Björklund A. The serotonergic system in L DOPA induced dyskinesia: pre-clinical evidence and clinical perspective. J Neural Transm (Vienna). 2018;8:1195–1202.
   Google Scholar
• Sebastianutto I, Maslava N, Hopkins CR, et al. Validation of an improved scale for rating L-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists. Neurobiol Dis. 2016;96:156–170.
   PubMed Web of Science ®Google Scholar
• Ahn S, Song TJ, Park SU, et al. Effects of a combination treatment of KD5040 and (L)-dopa in a mouse model of Parkinson’s disease. BMC Complement Altern Med. 2017;19:220.
   Google Scholar
• Breger LS, Dunnett SB, Lane EL. Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat. Neurobiol Dis. 2013;50:142–150.
   PubMed Web of Science ®Google Scholar
• Stansley BJ, Yamamoto BK. L-DOPA and brain serotonin system dysfunction. Toxics. 2015;3:75–88.
   PubMed Web of Science ®Google Scholar
• Calabrese V, Santoro A, Monti D, et al. Aging and Parkinson’s disease: inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis. Free Radic Biol Med. 2018;115:80–91.
   PubMed Web of Science ®Google Scholar
• Tran TN, TNN VO, FREI K, et al. Levodopa-induced dyskinesia: clinical features, incidence, and risk factors. J Neural Transm. 2018;125:1109–1117.
   PubMed Web of Science ®Google Scholar
• Guridi J, González-Redondo R, Obeso JA. Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson’s disease. Parkinson’s Dis. 2012;2012:1–15.
   Web of Science ®Google Scholar
• Dakheel ALA, Beaulieu-Boire I, Fox SH. Emerging drugs for levodopa-induced dyskinesia. Expert Opin Emerg Drugs. 2014;19:415–429.
   PubMed Web of Science ®Google Scholar
• Cenci MA, Crossman AR. Animal models of L-DOPA-induced dyskinesia in Parkinson’s disease. Mov Disord. 2018;33:1–11.
   PubMedGoogle Scholar
• Ueno T, Yamada J, Nishijima H, et al. Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia. Neurobiol Dis. 2014;64:142–149.
   PubMed Web of Science ®Google Scholar
• Minelli A, Conte C, Cacciatore I, et al. Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to L-DOPA in a Parkinson’s animal model. Amino Acids. 2012;43:1359–1367.
   PubMed Web of Science ®Google Scholar
• Dos-Santos-Pereira M, Da-Silva CA, Guimarães FS, et al. Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: possible mechanism of action. Neurobiol Dis. 2016;94:179–195.
   PubMed Web of Science ®Google Scholar
• Pagliaroli L, Widomska J, Nespoli E, et al. Riluzole attenuates L-DOPA-induced abnormal involuntary movements through decreasing CREB1 activity: insights from a rat model. Mol Neurobiol. 2018;56:5111–5121.
   PubMed Web of Science ®Google Scholar
• Lundblad M, Andersson M, Winkler C, et al. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. Eur J Neurosci. 2002;15:120–132.
   PubMed Web of Science ®Google Scholar
• Konta B, Frank W. The treatment of Parkinson’s disease with dopamine agonists. GMS Health Technol Assess. 2008;4:1–11.
   Google Scholar
• Bido S, Marti M, Morari M. Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels. J Neurochem. 2011;118:1043–1055.
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee HW, Hwang J, et al. Microglia-inhibiting activity of Parkinson’s disease drug amantadine. Neurobiol Aging. 2012;33:2145–2159.
   PubMed Web of Science ®Google Scholar
• Bortolanza M, Bariotto-dos-Santos KD, Dos-Santos-Pereira M, et al. Antidyskinetic effect of 7-nitroindazole and sodium nitroprusside associated with amantadine in a rat model of Parkinson’s disease. Neurotox Res. 2016;30:88–100.
   PubMed Web of Science ®Google Scholar
• Wolf E, Seppi K, Katzenschlager R, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov Disord. 2010;25:1357–1363.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rascol O. Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. J Neural Transm. 2018;125:1237–1250.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Damier P, Goetz CG, et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID study). Clin Neuropharmacol. 2004;27:58–62.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson’s disease: a double-blind placebo-controlled trial. Mov Disord. 2007;22:179–186.
   PubMed Web of Science ®Google Scholar
• Cenci MA, Lee CS, Björklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci. 1998;10:2694–2706.
   PubMed Web of Science ®Google Scholar
• Beck JK. Flibanserin for the treatment of extrapyramidal movement disorders. AU2002310813. 2002.
   Google Scholar
• Goldstein J. Method of Treatment. WO 2002049652. 2002
   Google Scholar
• Djaldetti R, Melamed E, Ziv I. Treatment of dyskinesias and parkinson’s disease with riluzole and L-DOPA. US 6417210. 2002
   Google Scholar
• Salvati P, Izzo E. Use of kynurenine-3-hydroxylase inhibitors for the preparation of medicaments for the treatment of L-DOPA induced movement disorders, dyskinesias, drug addiction, pain and cataract. WO2004098585. 2004.
   Google Scholar
• Weiner DM, Davis RE, Brann MR. Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases. WO 2004064738. 2004.
   Google Scholar
• Morari M, Marti M. Nop receptor agonists for the treatment of L-DOPA induced dyskinesias. WO 2008062296. 2008.
   Google Scholar
• Quik M, Monte DID, Langston JW. Methods and compositions for reduction of side effects of therapeutic treatments. US 20080260825 A1. 2008.
   Google Scholar
• Del Bello F, Giannella M, GIORGIONI G, et al. Receptor ligands as helping hands to L-DOPA in the treatment of Parkinson’s disease. Biomolecules. 2019;9:1–48.
   Web of Science ®Google Scholar
• Björklund A, Carta M, Lassen JB. Eltoprazine for suppression of L-DOPA induced dyskinesias. WO2004098585. 2009.
   Google Scholar
• Wikström H, Jørgensen M, Mørk N, et al. Treatment of dyskinesia related disorders. WO2010097092. 2010.
   Google Scholar
• Jordan KG, Letchworth SR, Bencherif M. Reversal of L-DOPA-induced dyskinesia by neuronal nicotinic receptor ligands. WO2010147938. 2010.
   Google Scholar
• Von Raison F, Weiner D, Roach A, et al. Safinamide in the treatment of dyskinesia. WO 2011098456. 2011.
   Google Scholar
• Mouradian MM, Braithwaite S, Voronkov M. Method of treating dyskinesia. WO2012149113. 2012.
   Google Scholar
• Ciallella J, Gruner J, Reaume AG, et al. Methods of treating dyskinesia and related disorders. WO2014145126. 2014.
   Google Scholar
• DJr S, Shen W. Targeting adenosine a2a receptors for the treatment of L-DOPA-induced dyskinesias. WO2018013951. 2018.
   Google Scholar
• Geva M, Orbach A, Hayden M. Pridopidine for treating drug induced dyskinesias. WO2019050775. 2019.
   Google Scholar
• Haddad F, Sawalha M, Khawaja Y, et al. Dopamine and levodopa prodrugs for the treatment of Parkinson’s disease. Molecules. 2018;23:1–17.
   Web of Science ®Google Scholar
• Müller T. Drug therapy in patients with Parkinson’s disease. Transl Neurodegener. 2012;1:1–10.
   PubMedGoogle Scholar